Omeros Corporation (OMER, Financial) experienced a significant stock price drop of 5.04%, with shares trading at $3.77. The trading volume reached 173,928 shares, translating to a turnover rate of 0.30% and price amplitude of 4.16%.
Financial reports indicate that Omeros registered no revenue with a net loss of $65.13 million. The earnings per share (EPS) stood at -$0.97, with a gross profit of -$208,000. The price-to-earnings ratio is currently -1.61.
Among the three rating agencies covering Omeros stock, 33% recommend buying, while 67% suggest holding. No agency advises selling the stock.
In the biotech sector, where Omeros operates, the overall decline was 0.05%. Notable performers include Silexion Therapeutics Corp, Cero Therapeutics Holdings Inc, and Lixte Biotechnology Holdings Inc, all of which saw significant gains. Meanwhile, Aditxt, Inc., Silexion Therapeutics Corp, and Sagimet Biosciences Inc. were the most active, with turnover rates of 689.86%, 592.18%, and 125.74% respectively. Tevogen Bio Holdings Inc, NLS Pharmaceutics Ltd, and TC Biopharm (Holdings) Plc exhibited notable price fluctuations.
Omeros Corporation focuses on developing and commercializing small-molecule and protein therapies for large markets, particularly targeting complement-mediated diseases, cancers, and addiction disorders. Their primary drug candidate, narsoplimab (OMS721), is in clinical development for conditions such as hematopoietic stem cell transplant-associated thrombotic microangiopathy and IgA nephropathy.
